Valuation dashboard for Curis, Inc. (CRIS) with P/E N/A, P/B 0.48, EV/EBITDA 0.09 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.
Analysis Summary
Curis, Inc. reported revenue of $9.4M in the most recent fiscal year, growing at a 5-year CAGR of -2.7%.
Trailing-twelve-month margins: gross margin 99.3%, operating margin -8.3%, net margin -490.3%.
At the current price of $1.12, CRIS has negative trailing earnings (P/E not meaningful) and an ROE of -10.35%. Market capitalisation stands at $2M.
Balance sheet quality for CRIS: current ratio of 0.5. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.48 |
| EV / EBITDA | 0.09 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CRIS | Curis, Inc. | $2M | 0.48 | -10.4% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $1.12 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -1035.26% |
| Return on Invested Capital | -567.17% |
| Return on Assets | -111.51% |
| Gross Margin | 99.28% |
| Operating Margin | -833.40% |
| Net Margin | -490.33% |
Related companies: ASBP · ATHA · BCTX · CTXR · ENTO · HOTH · ICU
Explore sector: Healthcare · Biotechnology
More sections of CRIS: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks